Drug reservoir stent

• US 20070173923A1
• Filed: 01/20/2006
• Published: 07/26/2007
• Est. Priority Date: 01/20/2006
• Status: Abandoned Application

• Current Assignee: Biosensors International Group, Ltd.
• Original Assignee: Biosensors International Group, Ltd.
• Inventors: Betts, Ronald, Savage, Douglas
• Application Number:
  US11/336,367
• Publication Number:
  US 20070173923A1
• Time in Patent Office: Days
• US Class Current: 623/1.150
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2002/041 Bile ducts
• CPC Class Codes: A61F 2002/047 Urethrae
• CPC Class Codes: A61F 2002/91533 characterised by the phase between adjacent bands
• CPC Class Codes: A61F 2230/0054 V-shaped
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir

Abstract

Drug reservoir stents and methods of making and using the same are described. Such drug reservoir stents are prepared by applying a sacrificial material to one or more surfaces of the strut filaments of a drug delivery stent and applying a durable coating material to the surface of the sacrificial material to create a durable shell. A drug reservoir is created between the surface(s) of the strut filament and the durable shell by creating at least one perforation in the durable shell and removing the sacrificial material. The resulting reservoir is then filled with one or more therapeutic drugs. The drug reservoir stent allows elution of drug in the absence of a polymer binder.

Claims

1. A drug delivery stent for implanting in a bodily passageway, lumen or duct, comprising:

a radially expandable stent body formed of one or more metallic or polymer strut filaments, each strut filament having outer, inner, side and end surfaces;

a drug reservoir composed of a therapeutic drug being carried on one or more surfaces of each strut filament; and

a durable shell coating covering said drug reservoir and having at least one perforation extending through the coating.

2. The stent of claim 1 wherein said drug reservoir has a thickness of between 2 and 30 microns.

3. The stent of claim 1 wherein the therapeutic drug is selected from the group consisting of an anti-restenosis drug, an anti-proliferative drug, an immunosuppressive compound, an antibiotic, an anti-thrombogenic drug and a cytotoxic compound.

4. The stent of claim 3 wherein the therapeutic drug is rapamycin, everolimus, paclitaxel, ABT-578, Biolimus A9, TRM-986, heparin, tranilast, beta-estradiol, or cyclosporin.

5. The stent of claim 1 wherein said durable shell coating comprises a polymer.

6. The stent of claim 5 wherein said polymer is parylene.

7. The stent of claim 1 wherein said reservoir further comprises a substantially inert binder.

8. The stent of claim 1 wherein said substantially inert binder is a polymer comprising poly(DL-lactide) or poly(L-lactide).

9. The stent of claim 1 wherein said shell covers at least the outer surface of substantially every filament of the stent.

10. A method of forming a drug delivery stent comprising the steps of:

applying a sacrificial material to at least one surface of each strut filament of a stent body formed of one or more filaments;

applying a durable coating material to said surface of said sacrificial material, creating a durable shell;

creating at least one perforation in said durable shell, and removing said sacrificial material to form a continuous reservoir disposed between said strut filament surface and said durable shell.

11. The method of claim 10 wherein said sacrificial material is applied substantially to the outer surface of each strut filament.

12. The method of claim 10 wherein said sacrificial material is applied substantially to the outer and side surfaces of each strut filament.

13. The method of claim 10 wherein said durable coating material comprises a polymer.

14. The method of claim 13 wherein said polymer is parylene.

15. The method of claim 10 wherein said sacrificial material comprises poly(D,L-lactide).

16. The method of claim 10 further comprising the step of filling said reservoir with a drug substance.